血清HBV RNA作为HBeAg阳性慢性乙型肝炎患者聚乙二醇干扰素α-2

StephenW

Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B
Florian van Bömmel Alena van Bömmel Alexander Krauel Cynthia Wat Vedran Pavlovic Lei Yang Danilo Deichsel Thomas Berg Stephan Böhm
The Journal of Infectious Diseases, Volume 218, Issue 7, 24 August 2018, Pages 1066–1074, https://doi.org/10.1093/infdis/jiy270
Published:
08 May 2018

Abstract
Background

Hepatitis B virus (HBV) RNA is a novel serum biomarker that has the potential to predict treatment response in patients with chronic hepatitis B. We explored whether HBV RNA serum levels can predict hepatitis B e antigen (HBeAg) seroconversion in patients treated with peginterferon alfa-2a.
Methods

Serum samples from HBeAg-positive patients previously treated with peginterferon alfa-2a in 2 large randomized controlled trials were retrospectively analyzed. HBV RNA levels were measured using a real-time polymerase chain reaction assay. Ability of individual biomarkers to predict HBeAg seroconversion at 24 weeks posttreatment was evaluated using receiver operating characteristics (ROC) analyses.
Results

The study included 131 subjects (70% male, 96% Asians, 35% HBV genotypes B, and 61% C), 76 treated with peginterferon alfa-2a alone and 55 in combination with lamivudine. Median HBV RNA levels were significantly lower, at all timepoints, in patients achieving HBeAg seroconversion. Levels of HBV RNA at treatment weeks 12 and 24 showed good ability to predict HBeAg seroconversion (area under ROC scores >0.75, P < .001). A HBV RNA cutoff of >5.5 log10 copies/mL identified 30% of nonresponders at week 12 (negative predictive value >90%).
Conclusion

Serum HBV RNA is an early predictor of HBeAg seroconversion in patients treated with peginterferon alfa-2a.
Clinical Trials Registration

NCT01705704.
PegIFN, stopping rules, CHB, biomarkers, HBV RNA, life cycle
Topic:

    biological markers hepatitis b e antigens hepatitis b, chronic hepatitis b virus rna peginterferon alfa-2a

Issue Section:
Viruses
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].

StephenW

血清HBV RNA作为HBeAg阳性慢性乙型肝炎患者聚乙二醇干扰素α-2a反应的预测因子
FlorianvanBömmelAlenavanBömmelAlexanderKrauel Cynthia Wat Vedran Pavlovic Lei Yang Danilo Deichsel Thomas BergStephanBöhm
“传染病杂志”，第218期，第7期，2018年8月24日，第1066-1074页，https：//doi.org/10.1093/infdis/jiy270
发布时间：
2018年5月8日

抽象
背景

乙型肝炎病毒（HBV）RNA是一种新型血清生物标志物，具有预测慢性乙型肝炎患者治疗反应的潜力。我们探讨了HBV RNA血清水平是否能预测聚乙二醇干扰素α治疗患者的乙型肝炎e抗原（HBeAg）血清学转换-2a。
方法

对2例大型随机对照试验中以聚乙二醇干扰素α-2a治疗的HBeAg阳性患者的血清样本进行回顾性分析。使用实时聚合酶链反应测定法测量HBV RNA水平。使用接受者操作特征（ROC）分析评估个体生物标志物在治疗后24周预测HBeAg血清转换的能力。
结果

该研究包括131名受试者（70％男性，96％亚洲人，35％HBV基因型B和61％C），76名单用聚乙二醇干扰素α-2a治疗，55名与拉米夫定联合治疗。在所有时间点，达到HBeAg血清转换的患者中位HBV RNA水平显着降低。治疗第12周和第24周的HBV RNA水平显示出良好的预测HBeAg血清转换的能力（ROC评分> 0.75，P <.001）。在第12周，HBV RNA截止值> 5.5log10拷贝/ mL确定了30％的无应答者（阴性预测值> 90％）。
结论

血清HBV RNA是聚乙二醇干扰素α-2a治疗患者HBeAg血清学转换的早期预测因子。
临床试验注册

NCT01705704。
PegIFN，停止规则，CHB，生物标志物，HBV RNA，生命周期
话题：

    生物标志物乙型肝炎抗原乙型肝炎，慢性乙型肝炎病毒rna聚乙二醇干扰素α-2a

问题部分：
病毒
©作者2018.牛津大学出版社出版的美国传染病学会。版权所有。对于权限，请发送电子邮件至：[email protected]。